Lacosamide is an Optimistic Option for Many Patients with Epilepsy

LacosamideLacosamide, CAS# 175481-36-4, is marketed under the trade name Vimpat. Previously known as erlosamide, lacosamide is a medication for both partial onset seizures. Often used in conjunction with other anti-eplileptic drugs, lacosamide is an anticonvulsant. LGM Pharma is not only a supplier of lacosamide, but they also offer support for clients throughout the research and development process.

By decreasing abnormal electrical activity in the brain, lacosamide is effective as an adjunctive therapy for many patients with epilepsy who are over seventeen years of age. Approved by the FDA in October of 2008 for seizures, lacosamide is also considered for pain management in patients with diabetic neuropathy. However, additional clinical trials are needed to determine if the FDA will approve lacosamide for neuropathic pain at a future date.

Absence SeizureOffered as an oral or IV therapy, lacosamide is initially given to patients as a 50 milligram dose, twice daily. Gradually the patient is increased to between 200-400 milligrams daily, taken twice a day. Studies have shown 400 milligram doses to be the maximum effective dose, as dosages of 600 milligrams caused a high incidence of adverse effects. Suicidal thoughts and depression, as well as dizziness, ataxia, syncope and atrial fibrillation have been reported by patients, though uncommon. Most common side effects reported include dizziness, nausea, vomiting, blurred vision, diarrhea, vertigo and fatigue.

A study reported in the European Journal of Epilepsy on 02/01/2012 indicated lacosamide to be a potential treatment for children with myoclonic epilepsy. This form of epilepsy is commonly diagnosed when a child is either at puberty or during his or her late teenage years. Roughly 15% of patients develop intractable myoclonic epilepsy, thus needing additional medications like lacosamide. Larger and more comprehensive studies are needed to confirm the use of lacosamide as both adjunctive and monotherapeutic therapy for patients suffering with myoclonic epilepsy, but initial data, albeit limited, is encouraging.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Tags:

Leave a Reply